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Abstract
Introduction
TP53 mutation and overexpression have been correlated with poor survival in many cancers
including oral squamous cell carcinoma (OSCC). We aim to understand the role of TP53
overexpression in OSCC in our population and correlate it with five-year survival to test its
viability as a prognostic marker for OSCC patients.
Materials and methods
Patients with biopsy proven OSCC at Aga Khan University Hospital from January 2000 to
January 2008 were recruited. Immunohistochemistry was used to establish TP53 status and the
results were published. Following up on these patients, five-year data were collected and
correlated with TP53 status and other clinicopathologic parameters.
Results
Overexpression of TP53 was not significantly associated with five-year survival (hazard ratio
[HR]: 1.543; 95% CI: 0.911-2.612; p = 0.107).
Conclusion
Although we had proven statistical relevance when correlated with overall survival in our
previous study, we were unable to extend the same relevance to TP53 overexpression when it
comes to five-year survival.
Categories: Otolaryngology, Pathology, Radiation Oncology
Keywords: oral squamous cell carcinoma (oscc), tp53, 5 year survival
Introduction
Oral squamous cell carcinoma (OSCC) is ranked as the eighth most common cancer, with global
incidence being 299,050 and 12,720 in Pakistan in 2012 [1]. An alarming statistic is that
Karachi, the largest city of Pakistan, bears the highest incidence of oral cavity cancer in the
world [2]. Moreover, a study conducted in Karachi stated that OSCC among low-income families
had increased by 200% from 1998 to 2002. According to the reports published by Pakistan
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Medical Research Council (PMRC), OSCC is the most common cancer among males and ranks
second highest among females [3]. The worldwide mortality for 2012 was 145,350, stressing
upon the need for effective management of the disease.
Emphasizing on the importance of this disease and its devastating consequences on our
population, research in the developmental mechanisms of OSCC holds immense importance.
The progress of OSCC at the molecular level is still unclear but latest developments present it
to be the result of environmental factors causing mutations in oncogenes and tumor
suppressor genes, particularly those involved in cell proliferation, differentiation, apoptosis
and deoxyribonucleic acid (DNA) repair [4].
Several risk factors are known to aid in the pathogenesis of OSCC: smoking, alcohol
consumption, chewing of betel quid and areca nut, and human papillomavirus infection [5].
Approximately 600 million people engage in betel quid chewing worldwide [5], making it the
fourth most common addictive substance used, following tobacco, alcohol, and caffeine [6]. A
study piloted in a squatter settlement of Karachi exposed that 40% of the population used betel
nut and tobacco regularly [7].
Among all the mutations found in OSCC, the TP53 tumor suppressor gene is most frequently
mutated [8-9]. The TP53 gene is located on the short arm of chromosome 17 and prevents
cancer formation by maintaining genomic stability and regulating the cell cycle. Different kinds
of stresses including oncogenic stimuli, ionizing radiation, UV radiation, hypoxia, cytokines
and growth factors can activate the TP53 through different pathways [10]. As the “guardian of
the genome”- p53 protein can initiate DNA repair proteins and stop the cell cycle at the G1/S
regulation point when the DNA is damaged or activate apoptosis if the DNA is damaged beyond
repair. When mutated, it allows cells to progress through DNA damage checkpoints and these
cells are allowed to replicate along with their harmful mutations.
It has been established by the International Cancer Genome Consortium that the missense
mutation is the most commonly occurring type (79%) among all TP53 mutations [11]. Mutations
in TP53 make it more stable and hence easy to detect by immunohistochemistry [12]. However,
any loss-of-function mutation in the TP53 does not directly transform the cells into neoplastic
cells as loss of guardian function has no direct effect on proliferation. Instead, it permits the
DNA to get damaged easily leading to mutations, acquisition of oncogenes, and neoplastic
activity.
To date, even after intense research in management options, the five-year survival rate
for OSCC has not increased significantly [13]. There have been very few studies on OSCC five-
year survival worldwide and no studies to date in Pakistan, to the best of our knowledge. There
have been a number of studies on one- and two-year survival but it is difficult to use such data
to form conclusions in cancers like OSCC as these patients usually live for up to more than two
years which stresses the need for five-year survival studies. Furthermore, the association of
TP53 mutation and five-year survival of OSCC patients is still unclear. Correlation of TP53
mutation with gender, age, OSCC risk factors like alcohol and tobacco, site and grading are
currently being established in different researches around the world in order to provide detailed
information on OSCC patient prognosis at the time of presentation.
We have previously carried out and published a study discussing TP53 expression in terms of
overall survival which concerned the same patient data set [14]. Five-year follow-up data for
these patients was unavailable at the time of that study, as they had been freshly recruited, thus
the aim of that study was to understand TP53 expression in terms of overall survival, as the
duration of survival varied greatly among the patients. Subsequently, the aim of this study is to
continue work on these patients and establish any and all such correlations between TP53
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mutation and OSCC patient prognosis using a fixed five-year survival rate as it is the optimum
method to validate prognostic use of any marker.
Materials And Methods
The study was a case series including 140 patients with primary OSCC who had been diagnosed
and treated at Aga Khan University Hospital (AKUH), Karachi, Pakistan from January 2000 to
January 2008. The study was approved by the Ethical Review Committee at AKUH and written
informed consent was taken from all patients prior to their induction in the study. Inclusion
criteria consisted of complete clinicopathologic data and presence of five-year follow-up data.
Clinicopathologic information on each case including gender, age, TP53 overexpression, use of
betel nut and/or other substances, smoking or alcohol consumption either alone or in different
combinations, the site of OSCC, American Joint Committee on Cancer (AJCC) staging, tumor
size, nodal involvement and metastasis was collected from our previously conducted study [14].
Additional five-year follow-up was obtained for all patients and they were classified as either
alive or dead after 60 months. Immunohistochemistry was used in our previously reported
study to assess TP53 overexpression using primary antibody TP53 (mouse monoclonal anti-
TP53, clone DO-7, Dako Cytomation, diluted 1:50).
The results were recorded by the study investigators and data was analyzed using SPSS version
19 (IBM, NY, USA). Potential associations between demographic, histological, clinical
parameters and five-year survival were assessed. Follow-up times for each patient were
measured in months and mean survival was calculated from the date of diagnosis until death or
for 60 months, whichever occurred sooner. Univariate Cox analysis was done to investigate the
effect of clinicopathologic factors on mean five-year survival and a multivariate analysis was
done for AJCC staging and TP53 positivity. A Kaplan-Meier curve was plotted to assess the
event point distribution over a period of 60 months.
Results
Patient characteristics
The total sample size was 140, with 69 patients expiring (event) and 71 alive (censored) at the
end of 60 months. In our study, 82 patients (59%) were males and 58 (41%) were females with a
male-female ratio of 1.4:1 and 112 (80%) patients were >40 years of age. The most frequently
occurring primary lesion location was cheek (86) followed by tongue (54), mandible (36), palate
(14), retromandible (17) and the floor of the mouth (14). Additionally, the highest number of
patients presented with AJCC stage II disease (34%), followed by stage III (27%), stage IV (22%)
and stage I (19%). Based on the disease stage, 82 (59%) patients were treated with surgery and
radiation both while 58 (41%) were treated with surgery alone. Most commonly used addictive
substance for our patients was betel quid, followed by tobacco. Table 1 shows the demographic
details of the patients.
 
Event (n = 69) Censored (n = 71) Total (n = 140)
Count Column N% Count
Column N
% Count
Column N
%
Gender
Male 40 58.0% 42 59.2% 82 58.6%
Female 29 42.0% 29 40.8% 58 41.4%
Age group
<40 years 11 15.9% 17 23.9% 28 20.0%
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>= 40 years 58 84.1% 54 76.1% 112 80.0%
TP53 value
Positive 49 71.0% 45 63.4% 94 67.1%
Negative 20 29.0% 26 36.6% 46 32.9%
Positivity
Mild 8 11.6% 11 15.5% 19 13.6%
Moderate 15 21.7% 7 9.9% 22 15.7%
Strong 26 37.7% 27 38.0% 53 37.9%
Negative 20 29.0% 26 36.6% 46 32.9%
Histological classification of
tumor
W-D-SCC 26 37.7% 29 40.8% 55 39.3%
M-D-SCC 41 59.4% 38 53.5% 79 56.4%
P-D-SCC 2 2.9% 4 4.1% 6 4.3%
AJCC_STAGE
I 9 13.0% 18 25.4% 27 19.3%
II 18 26.1% 26 36.6% 44 31.4%
III 22 31.9% 16 22.5% 38 27.1%
IV 20 29.0% 11 15.5% 31 22.1%
Smoking
Yes 26 37.7% 25 41.7% 51 36.4%
No 43 62.3% 35 58.3% 89 63.6%
Betel quid chewer
Yes 43 62.3% 39 54.9% 82 58.6%
No 26 37.7% 32 45.1% 48 34.4%
Tobacco
Yes 20 29.0% 23 32.4% 43 30.7%
No 49 71.0% 48 67.6% 97 69.3%
Cheek/tongue
Cheek 48 69.6% 38 53.5% 86 61.4%
Tongue 21 30.4% 33 46.5% 54 38.6%
Palate
Yes 6 8.7% 8 11.3% 14 10.0%
No 63 91.3% 63 88.7% 126 90.0%
Mandible
Yes 18 26.1% 18 25.4% 36 25.7%
No 51 73.9% 53 74.6% 104 74.3%
Retromandibular
Yes 11 15.9% 6 8.5% 17 12.1%
No 48 69.6% 51 71.8% 99 70.7%
NA 10 14.5% 14 19.7% 24 17.1%
Floor of mouth
Yes 4 5.8% 10 14.1% 14 10.0%
No 65 94.2% 61 85.9% 126 90.0%
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Tonsil
Yes 1 1.4% 2 2.8% 3 2.1%
No 68 98.6% 69 97.2% 137 97.9%
Nodal status physical
Palpable node 31 44.9% 26 36.6% 57 40.7%
No palpable
node 38 55.1% 45 63.4% 83 59.3%
Single/multiple nodes
Single 20 29.0% 19 26.8% 39 27.9%
Multiple 11 15.9% 7 9.9% 18 12.9%
NA 38 55.1% 45 63.3% 83 59.3%
Final T stage
T1 12 17.4% 21 29.6% 33 23.6%
T2 31 44.9% 33 46.5% 64 45.7%
T3 12 17.4% 10 14.1% 22 15.7%
T4 14 20.3% 7 9.8% 21 15.0%
Final N stage
N0 43 62.3% 59 83.1% 102 72.9%
N1 18 26.1% 8 11.3% 26 18.6%
N2a 2 2.9% 1 1.4% 3 2.1%
N2b 6 8.7% 3 4.2% 9 6.4%
Final M stage M0 69 100.0% 71 100.0% 140 100.0%
 Neck pathology
Negative 27 39.1% 44 62.0% 71 50.7%
Positive 25 36.2% 13 18.3% 38 27.1%
ND 17 24.6% 14 19.7% 31 22.1%
TABLE 1: Patient demographics at five-year follow-up (n = 140).
Out of 140 tumors, 94 (67%) patients were TP53 positive and 46 (33%) patients were TP53
negative. TP53 overexpression was not significantly correlated with any clinicopathologic
parameters tested, such as AJCC staging, habits, histology and final T and N stages. A total of
54 patients presented with tongue as the primary site of tumor, with 51 patients having tumor
in the anterior tongue, five in the posterior and two patients having both. However, a
significant association was observed between the anterior tongue as the site of tumor and TP53
positivity (p = 0.038). Table 2 shows TP53 expression and clinicopathologic parameters.
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Characteristic  P53 overexpressionpositive
P53 overexpression
negative
Pearson Chi-Square
value
p-
value
AJCC staging Stage I 21 6
5.247 0.155
 Stage II 33 11
 Stage III 22 16
 Stage IV 18 13
Habits Smoking/tobacco 35 16 0.090 0.956
 Pan/supari 57 25 0.612 0.736
 Naswar/chalia/gutka 28 15 0.242 0.886
Final T stage Stage I 23 10
4.439 0.218
 Stage II 47 17
 Stage III 11 11
 Stage IV 13 8
Final N stage N0 70 32
0.560 0.756 N1 17 9
 N2 7 5
Histology W-D-SCC 38 17
0.894 0.640 M-D-SCC 53 26
 P-D-SCC 3 3
Site of tumor Anterior tongue 30 23 4.294 0.038
 Posterior tongue 4 1 0.389 0.533
 Palate 10 4 0.130 0.719
 Mandible 23 13 0.233 0.630
 Retromandibular 11 6 0.387 0.824
 Floor of mouth 9 5 0.058 0.810
 Tonsil 3 0 1.500 0.221
TABLE 2: Correlation of P53 overexpression and clinicopathologic parameters.
Furthermore, AJCC staging, final N stage and neck pathology were found statistically
significant on univariate analysis (p = 0.003, p < 0.001 and p = 0.003, respectively) (Table 3).
Moreover, AJCC staging remained significant (p = 0.003) on multivariate analysis using COX
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regression, while TP53 persisted statistically insignificant.
Mean and median survival time
AJCC stage I was associated with significantly longer survival (49.9 months, 95% CI: 41.9-57.9)
as compared to stage IV (31.8 months, 95% CI: 22.9-40.6) as shown in Table 3. Additionally, the
absence of neck pathology displayed significantly longer survival (50.2 months, 95% CI: 45.8-
54.5). Table 3 shows the univariate and multivariate analysis.
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Univariate Analysis
Factor Hazard ratio or Exp(B)
95.0% CI for Exp(B)
Sig.
Lower Upper
TP53 value
Positive 1    .265
Negative 1.344 .798 2.262  
AJCC_STAGE
I .326 .148 .716 .003
II .361 .191 .684  
III .560 .305 1.028  
IV 1    
Final N stage
N0 .249 .105 .592 <0.001
N1 .560 .221 1.417  
N2a 2.573 .494 13.385  
Neck pathology
Negative .584 .318 1.072 .003
Positive 1.482 .799 2.747  
Multivariate Analysis
 
 
Adjusted hazard ratio Exp(B)
95.0% CI for Exp(B)
Sig.
 Lower Upper
AJCC_STAGE
    .003
I 1.114 0.500 2.481  
II 1.823 0.837 3.972  
III 3.309 1.497 7.316  
TP53 value
Positive  1.543 0.911 2.612 .107
Negative 1    
TABLE 3: Univariate and multivariate analysis.
TP53 positivity and survival
All clinical features in Table 1 were examined to determine any correlation with TP53
overexpression using Pearson Chi-square test and it was found that TP53 overexpression was
not significantly correlated with any clinicopathologic factor (HR: 1.543; 95% CI: 0.911-2.612,
p = 0.107). Additionally, TP53 overexpression was also not statistically significant on univariate
analysis (p = 0.265) (Table 3). Furthermore, there was no marked difference in mean survival
time of TP53 positive (44.258, 95% CI: 39.918-48.597) and TP53 negative (46.676, 95% CI:
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40.314-53.039) patients. Table 4 shows mean and median survival time.
 
Meana Median
Estimate Std. error
95% confidence interval
Estimate Std. error
95% Confidence interval
Lower bound Upper bound Lower bound Upper bound
Overall 45.079 1.821 41.511 48.648 60.000 .964 58.111 61.889
TP53 value         
Positive 44.258 2.214 39.918 48.597 60.000 2.669 54.769 65.231
Negative 46.676 3.246 40.314 53.039     
Positivity         
Mild 53.500 3.618 46.409 60.591 60.000    
Moderate 36.994 4.513 28.148 45.841 32.000 3.737 24.676 39.324
Strong 43.894 3.107 37.805 49.983 60.000 4.226 51.717 68.283
Negative 46.676 3.246 40.314 53.039     
AJCC_STAGE         
I 49.944 4.093 41.921 57.967     
II 51.417 2.432 46.652 56.183     
II 44.831 3.397 38.173 51.488 60.000 7.122 46.041 73.959
IV 31.809 4.514 22.962 40.656 19.000 9.947 0.000 38.496
Final T stage         
T1 50.711 3.441 43.966 57.456     
T2 46.970 2.474 42.122 51.819 60.000 1.360 57.335 62.665
T3 43.905 4.815 34.468 53.342 60.000 11.148 38.149 81.851
T4 32.813 5.390 22.249 43.376 26.000 11.006 4.429 47.571
Final N stage         
N0 49.019 1.938 45.220 52.818     
N1 37.211 4.386 28.614 45.808 32.000 4.718 22.753 41.247
N2a 12.500 .500 11.520 13.480 12.000    
N2b 28.857 8.385 12.423 45.292 19.000 6.547 6.169 31.831
Neck pathology         
Negative 50.211 2.208 45.884 54.539     
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Positive 37.573 3.880 29.969 45.178 40.000 7.767 24.776 55.224
ND 42.464 4.081 34.465 50.462 60.000 11.262 37.927 82.073
TABLE 4: Mean and median survival time.
However, mild degree of positivity was found to be associated with longer survival (53.5, CI:
46.4-60.6) as compared to moderate degree of positivity (36.99, CI: 28.1-45.8). A Kaplan-Meier
curve plotted as shown in Figure 1 for fixed five-year survival illustrated no significant
difference in survival between TP53 positive and negative groups with Log Rank 0.239.
FIGURE 1: Kaplan-Meier curve depicting five-year survival of
p53 positive and negative oral squamous cell carcinoma
(OSCC) patients.
Discussion
The carcinogenesis of the gastrointestinal tract epithelium is an intricate process that involves
abnormalities of oncogenes and tumor suppressor genes [15-16]. Even today it is not clear why
patients having identical tumor grading and staging behave differently when confronted with
similar treatments. This may be due to unique molecular changes resulting from differing
expression of certain genes.
Western countries have a high incidence of TP53 mutations in OSCC associated with these risk
factors [17] with India [18] reported to have low incidence and Taiwan [19] with high incidence
from Asia. We report no association of these risk factors including smoking, tobacco and betel
quid usage with TP53 over expression.
Environmental insults are known to be one of the root causes of oral cancer, considering that
this malignancy occurs almost exclusively in patients with tobacco, alcohol and/or betel quid
usage and these agents are believed to cause a synergistic carcinogenic effect on the oral cavity
[5]. The independent effect of these risk factors is difficult to ascertain considering that most
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subjects are using a combination of these risk factors and as a result multiple conflicting
outcomes have been reported.
Of all related genes, TP53 has received foremost attention: Its prevalence in head and neck
squamous cell cancer varies from 30% to 70% [20]. Almost all types of cancers are reported to
have TP53 mutations, from 10% in hematopoietic malignancies to close to 100% in high-grade
serous carcinoma of the ovary [21]. According to “The TP53 website” lung cancers have the
highest TP53 mutation rate (70%) followed by colorectal (60%) and head and neck cancers
(60%). Laryngeal squamous cell carcinoma is severely implicated in TP53 overexpression and
so is the progression of non-malignant lesions to malignant ones, but for the prognostic
significance of TP53 and observing its value for the entire head and neck squamous cell cancer
group, results differ among studies.
In the past, there have been studies showing no correlation between TP53 expression and
patient prognosis, regardless of whether the analysis involved only the invasive fronts of
tumors [22], or tumors as a whole [23]. On the other hand in a study conducted on 16 patients
with recurrent squamous cell carcinoma of the head and neck, a poor prognosis with positive
TP53 expression was observed [24].
The presence of TP53 mutation was associated with a significantly decreased overall survival
and even stronger association with disruptive mutations as shown by Poeta, et al. [25].
However, other multiple attempts have turned out inconclusive in correlating TP53 status and
survival. The diversity of results may partly be due to: a diverse and small sample size, the
tissue type analyzed and the methods used for analysis including antibodies, tissue treatment
and the threshold set for positivity and negativity of stained sections [26].
In our study we observed that neither the histological differentiation nor the consumption of
addictive substances or any other risk factors were associated with TP53 overexpression, only
the location of tumor was significant for the anterior tongue showing most TP53 expression.
AJCC staging, nodal status, and neck pathology were significantly associated with TP53
overexpression in univariate analysis but lost their significance in the multivariate analysis.
This is in accordance with other reports including Field, et al. which reported no correlation
between TP53 overexpression and any other clinicopathological parameters [27]. However,
some previous reports [17] have described accumulating TP53 levels correlating with increasing
histological severity and with anatomical site of the tumor.
Conclusions
An ideal marker predicting tumor prognosis should indicate tumor formation when present and
should exclude such possibility on absence and to identify such a marker the five-year survival
analysis is indispensable. Our previous study highlighted the importance of TP53 mutation
when dealt with overall survival ranging from months to years. Following up on these patients,
however, displayed that TP53 overexpression could not be held statistically significant over
five-year survival. This could be due to the differing anatomical location of tumor in our patient
set, the type of exposure and sample size. However, it is unlikely that a single tumor marker
can predict tumor progression since the development and progression of a tumor is a
cumulative response to various factors. Therefore, it is equally important to look at the status
of other factors closely related to TP53. Nevertheless, the TP53 pathway is a very important
one in head and neck squamous cell cancer pathogenesis and also potentially in its
management. We believe that TP53 overexpression estimation may eventually prove useful as a
routine component of tumor assessment along with tumor staging.
Additional Information
2017 Ali et al. Cureus 9(6): e1401. DOI 10.7759/cureus.1401 11 of 13
Disclosures
Human subjects: Consent was obtained by all participants in this study. The study was
approved by the Ethical Review Committee at AKUH and written informed consent was taken
from all patients prior to their induction in the study. Animal subjects: This study did not
involve animal subjects or tissue. Conflicts of interest: The authors have declared the
following conflicts of interest: Payment/services info: This study was supported by a grant
from university research council, the Aga Khan University, Karachi, Pakistan. Grant ID:
031018SURG.
Acknowledgements
This study was supported by a grant from university research council, the Aga Khan University,
Karachi, Pakistan. Grant ID: 031018SURG.
References
1. Ferlay J, Soerjomataram I, Dikshit R, et al.: Cancer incidence and mortality worldwide:
sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015, 136:359–386.
10.1002/ijc.29210
2. Bhurgri Y: Cancer of the oral cavity - trends in Karachi South (1995-2002) . Asian Pac J Cancer
Prev. 2005, 6:22–26.
3. Bhurgri Y, Bhurgri A, Nishter S, et al.: Pakistan--country profile of cancer and cancer control
1995-2004. J Pak Med Assoc. 2006, 56:124–130.
4. Vogelstein B, Papadopoulos N, Velculescu VE, et al.: Cancer genome landscapes. Science.
2013, 339:1546–1558. 10.1126/science.1235122
5. Chaturvedi P: Areca nut or betel nut control is mandatory if India wants to reduce the burden
of cancer especially cancer of the oral cavity. Int J Head Neck Surg. 2010, 1:17–20. 10.5005/jp-
journals-10001-1003
6. Gupta PC, Ray CS: Epidemiology of betel quid usage . Ann Acad Med Singapore. 2004, 33:31–
36.
7. Khawaja MR, Mazahir S, Majeed A, et al.: Knowledge, attitude and practices of a Karachi slum
population regarding the role of products of betel, areca and smokeless tobacco in the
etiology of head & neck cancers. J Pak Med Assoc. 2005, 55:S41.
8. Rothenberg SM, Ellisen LW: The molecular pathogenesis of head and neck squamous cell
carcinoma. J Clin Invest. 2012, 122:1951–1957. 10.1172/JCI59889
9. Surget S, Khoury MP, Bourdon JC: Uncovering the role of p53 splice variants in human
malignancy: a clinical perspective. Onco Targets Ther. 2013, 7:57-68. 10.2147/OTT.S53876
10. de Stanchina E, McCurrach ME, Zindy F, et al.: E1A signaling to p53 involves the p19(ARF)
tumor suppressor. Genes Dev. 1998, 12:2434–2442.
11. Greenblatt MS, Bennett WP, Hollstein M, et al.: Mutations in the p53 tumor suppressor gene:
clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994, 54:4855–4878.
12. Lane DP, Hall PA: MDM2--arbiter of p53's destruction. Trends Biochem Sci. 1997, 22:372–
374. 10.1016/S0968-0004(97)01119-5
13. Mork J, Glattre E: Squamous cell carcinomas of the head and neck in Norway, 1953-92: an
epidemiologic study of a low-risk population. Cancer Causes Control. 1998, 9:37–48.
10.1023/A:1008845219266
14. Ali SMA, Awan MS, Ghaffar S, et al.: TP53 protein overexpression in oral squamous cell
carcinomas (OSCC): correlation with histologic variables and survival outcome in Pakistani
patients. Oral Surgery. 2010, 3:83-95. 10.1111/j.1752-248X.2010.01089.x
15. Bishop JM: Molecular themes in oncogenesis . Cell. 1991, 64:235–248. 10.1016/0092-
8674(91)90636-D
16. Vokes EE, Weichselbaum RR, Lippman SM, et al.: Head and neck cancer. N Engl J Med. 1993,
328:184–194. 10.1056/NEJM199301213280306
17. Ostwald C, Gogacz P, Hillmann T, et al.: p53 mutational spectra are different between
squamous-cell carcinomas of the lip and the oral cavity. Int J Cancer. 2000, 88:82–86.
10.1002/1097-0215(20001001)88:1<82::AID-IJC13>3.0.CO;2-N
2017 Ali et al. Cureus 9(6): e1401. DOI 10.7759/cureus.1401 12 of 13
18. Saranath D, Tandle AT, Teni TR, et al.: p53 inactivation in chewing tobacco-induced oral
cancers and leukoplakias from India. Oral Oncol. 1999, 35:242–250. 10.1016/S1368-
8375(98)00110-9
19. Su SC, Lin CW, Liu YF, et al.: Exome sequencing of oral squamous cell carcinoma reveals
molecular subgroups and novel therapeutic opportunities. Theranostics. 2017, 7:1088-1099.
10.7150/thno.18551
20. Ko Y, Abel J, Harth V, et al.: Association of CYP1B1 codon 432 mutant allele in head and neck
squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res.
2001, 61:4398–4404.
21. Ahmed AA, Etemadmoghadam D, Temple J, et al.: Driver mutations in TP53 are ubiquitous in
high grade serous carcinoma of the ovary. J Pathol. 2010, 221:49–56. 10.1002/path.2696
22. Piffko J, Bankfalvi A, Tory K, et al.: Molecular assessment of p53 abnormalities at the invasive
front of oral squamous cell carcinomas. Head Neck. 1998, 20:8–15. 10.1002/(SICI)1097-
0347(199801)20:1<8::AID-HED2>3.0.CO;2-8
23. Nylander K, Schildt EB, Eriksson M, et al.: PCNA, Ki-67 p53, bcl-2 and prognosis in intraoral
squamous cell carcinoma of the head and neck. Anal Cell Pathol. 1997, 14:101–110.
10.1155/1997/591251
24. Sauter ER, Ridge JA, Litwin S, et al.: Pretreatment p53 protein expression correlates with
decreased survival in patients with end-stage head and neck cancer. Clin Cancer Res. 1995,
1:1407–1412.
25. Poeta ML, Manola J, Goldwasser MA, et al.: TP53 mutations and survival in squamous-cell
carcinoma of the head and neck. N Engl J Med. 2007, 357:2552–2561. 10.1056/NEJMoa073770
26. Nylander K, Dabelsteen E, Hall PA: The p53 molecule and its prognostic role in squamous cell
carcinomas of the head and neck. J Oral Pathol Med. 2000, 29:413–425. 10.1034/j.1600-
0714.2000.290901.x
27. Field JK, Pavelic ZP, Spandidos DA, et al.: The role of the p53 tumor suppressor gene in
squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1993,
119:1118–1122. 10.1001/archotol.1993.01880220064009
2017 Ali et al. Cureus 9(6): e1401. DOI 10.7759/cureus.1401 13 of 13
